BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Senhwa Biosciences Advances CX 5461 Into ADC Combination Trial With Enhertu Backed By US NCI

Senhwa Biosciences has announced a significant clinical milestone with its investigational drug Pidnarulex CX 5461 advancing into a Phase 1...

December 30, 2025 | News

Alphamab Oncology Secures IND Acceptance In China For JSKN033 Phase II Cervical Cancer Study

Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcu...

December 30, 2025 | News

Niowave Extends Actinium 225 Supply Agreement With AstraZeneca To Support Next Generation Cancer Therapies

Niowave will expand its agreement to supply Actinium-225, a highly promising medical isotope, to AstraZeneca 10-year supply agreement ...

December 29, 2025 | News

China Approves First Dual Immunotherapy Neoadjuvant Regimen For MSI H dMMR Colon Cancer

TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment o...

December 26, 2025 | News

SN Bioscience Secures US FDA Orphan Drug Designation For SNB 101 In Gastric Cancer

SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (incl...

December 25, 2025 | News

HKSH Medical Group And Shenzhen Cancer Hospital Formalise Proton Therapy Collaboration Under Healthy China 2030 Framework

In alignment with the national framework for the advancement of proton therapy, facilitated by the National Cancer Center, HKSH Medical Group ("HKSH")...

December 25, 2025 | News

Japan Approves Guardant360 CDx As First Blood Based Companion Diagnostic For ESR1 Mutations In Breast Cancer

Guardant360® CDx is the first companion diagnostic to be approved in Japan to identify ESR1 mutations in patients with hormone receptor-posit...

December 23, 2025 | News

Japan Approves Incyte’s Zynyz As First Line Treatment For Advanced Anal Canal Cancer

Incyte Biosciences Japan G.K. announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination w...

December 23, 2025 | News

Alphamab Oncology’s JSKN003 Gains FDA Breakthrough Therapy Designation For Platinum Resistant Ovarian Cancer

Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the...

December 23, 2025 | News

Ferronova Raises $6 Million To Advance Nanoparticle Guided Cancer Surgery Technology

Australian company Ferronova has raised a further $6 million to progress the commercialisation of a novel nanoparticle image-guided surgery solut...

December 18, 2025 | News

Akeso Secures FDA Clearance to Launch Global Phase III Gastric Cancer Trial of Cadonilimab

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in ...

December 15, 2025 | News

D3 Bio Secures One Hundred 8M$ In Series B Funding To Advance Global Late Stage Oncology Trials

D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completio...

December 11, 2025 | News

Lunit Submits FDA 510k For AI Driven Five Year Breast Cancer Risk Prediction Model

Submission marks a key regulatory milestone toward bringing SEER-calibrated, imaging-based risk assessment to U.S. screening programs Lunit (KRX:328130), ...

December 09, 2025 | News

Mango Sciences Partners with ImmunoACT to Expand Access to NexCAR19 CAR-T Therapy in India

Mango Sciences, Inc., the Boston, US, and Bengaluru, IN-based data and AI company, announced a strategic partnership with ImmunoAdoptive Cell Therapy (Immu...

December 08, 2025 | News

Stay Connected